CHGA and neuroendocrine neoplasm: Besides typical morphology, well-known biomarkers for PCC/PGLs are positive immunohistochemistry for chromogranin A, synaptophysin, and S100; however, this does not allow differentiation from any other neuroendocrine tumors.